View Older Stories View More Recent Stories

May 6, 2021 08:00AM Daré Bioscience to Host First Quarter 2021 Financial Results and Company Update Conference Call and Webcast on May 13, 2021
Apr 27, 2021 08:00AM Daré Bioscience Announces Ovaprene®, a Novel Investigational Hormone-Free Contraceptive, Poster Presentation at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricia
Apr 26, 2021 08:00AM Daré Bioscience Announces the Presentation of DARE-BVFREE Phase 3 Clinical Trial Results at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists
Apr 19, 2021 08:00AM Daré Bioscience Appoints Dr. Sophia N. Ononye-Onyia to its Board of Directors
Mar 30, 2021 08:00AM Daré Bioscience Reports Full Year 2020 Financial Results and Provides a Company Update
Mar 24, 2021 08:07AM Dare Bioscience (DARE) Announces Initiation of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
Mar 24, 2021 08:00AM Daré Bioscience Announces Initiation of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
Mar 23, 2021 08:00AM Daré Bioscience to Host Full Year 2020 Financial Results and Company Update Conference Call and Webcast on March 30, 2021
Mar 22, 2021 08:07AM Dare Bioscience (DARE) Reports Complete Recruitment in Phase 1 Clinical Trial of DARE-HRT1
Mar 22, 2021 08:00AM Daré Bioscience Completes Recruitment in Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-Oral, Bio-identical Hormone Therapy for the Treatment of Vasomotor Symp
Mar 10, 2021 08:00AM Daré Bioscience to Participate in Upcoming Virtual Conferences
Mar 8, 2021 08:00AM Daré Bioscience to Participate at the 33rd Annual Roth Conference
Mar 2, 2021 08:00AM Daré Bioscience to Present at the H.C. Wainwright Global Life Sciences Conference
Feb 25, 2021 08:00AM Daré Bioscience to Participate in Maxim Group’s Late Stage Innovations in Women’s Health Virtual Event
Feb 16, 2021 08:00AM Daré Bioscience to Participate at the Women’s Health Innovation Series: Contraception Innovation Summit to be held Virtually on February 23, 2021
Feb 9, 2021 08:00AM Daré Bioscience to Present at the 2021 BIO CEO & Investor Digital Conference
Jan 5, 2021 08:00AM Daré Bioscience to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
Dec 7, 2020 08:05AM Dare Bioscience (DARE) Phase 3 Trial of DARE-BV1 in Patients Diagnosed with Bacterial Vaginosis Met Primary Endpint
Dec 7, 2020 08:00AM Daré Bioscience Announces Positive Topline Results From DARE-BVFREE, a Phase 3 Trial of DARE-BV1 in Patients Diagnosed with Bacterial Vaginosis
Nov 12, 2020 08:00AM Daré Bioscience Reports Third Quarter 2020 Financial Results and Provides Company Update
Nov 5, 2020 08:00AM Daré Bioscience to Host Third Quarter 2020 Financial Results and Company Update Conference Call and Webcast on November 12, 2020
Oct 7, 2020 08:00AM Daré Bioscience to Present at the 2020 BIO Investor Forum Digital
Sep 21, 2020 08:08AM Dare Bioscience (DARE) Receives $0.9 million Under the Current Grant Supplement Award for Continued Development of its User-Controlled, Long Acting Reversible Contraceptive
Sep 21, 2020 08:00AM Daré Bioscience Receives $0.9 million Under the Current Grant Supplement Award for Continued Development of its User-Controlled, Long Acting Reversible Contraceptive (DARE-LARC1)
Sep 8, 2020 08:00AM Daré Bioscience Announces Participation in Two Upcoming Virtual Conferences
Sep 1, 2020 08:04AM Daré Bioscience and Avomeen Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs
Aug 20, 2020 08:02AM Dare Bioscience (DARE) Announces Publication of DARE-BV1 Proof of Concept Study for the Treatment of Bacterial Vaginosis
Aug 20, 2020 08:00AM Daré Bioscience Announces Publication of DARE-BV1 Proof of Concept Study for the Treatment of Bacterial Vaginosis
Aug 19, 2020 08:05AM Dare Bioscience (DARE) Announces Funding Award Notice from NIH Eunice Kennedy Shriver NICHD to Support DARE-FRT1 Phase 1 Human Clinical Study
Aug 19, 2020 08:00AM Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-FRT
Aug 12, 2020 08:00AM Daré Bioscience Reports Second Quarter 2020 Financial Results and Provides Company Update
Aug 6, 2020 08:00AM Daré Bioscience CEO to Participate in Maxim Group’s Leading Innovators in Women’s Health Virtual Conference
Aug 5, 2020 08:00AM Daré Bioscience to Host Second Quarter 2020 Financial Results and Company Update Conference Call and Webcast on August 12, 2020
Jul 27, 2020 08:04AM Dare Bioscience (DARE) Begins Phase 1 Clinical Trial of DARE-HRT1
Jul 27, 2020 08:00AM Daré Bioscience Announces Initiation of Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-oral, Bio-identical Hormone Therapy for the Treatment of Menopausal Symp
Jun 24, 2020 08:11AM Dare Bioscience (DARE) Announces Publication of Peer-Reviewed Journal Article Supporting Use of Postcoital Test Study as Predictor of Contraceptive Effectiveness by Biology of Reproduction
Jun 24, 2020 08:00AM Daré Bioscience Announces Publication of a Peer-Reviewed Journal Article Supporting the Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Biology of Reproduction
Jun 17, 2020 08:02AM Dare Bioscience (DARE) Begins Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis
Jun 17, 2020 08:00AM Daré Bioscience Announces Initiation of Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis
Jun 15, 2020 08:04AM Dare Bioscience (DARE) Announces Receipt of $1.5 Million Under Current Grant Supplement Award for Continued Development of User-Controlled Long Acting Reversible Contraceptive
Jun 15, 2020 08:00AM Daré Bioscience Announces Receipt of $1.5 Million Under the Current Grant Supplement Award for Continued Development of User-Controlled Long Acting Reversible Contraceptive
Jun 4, 2020 08:00AM Daré Bioscience Announces Participation in BIO Digital 2020
May 14, 2020 08:00AM Daré Bioscience Reports First Quarter 2020 Financial Results and Provides Company Update
May 11, 2020 08:10AM Dare Bioscience (DARE), Health Decisions Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs
May 11, 2020 08:00AM Daré Bioscience and Health Decisions Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs
May 7, 2020 08:00AM Daré Bioscience to Host First Quarter 2020 Financial Results and Company Update Conference Call and Webcast on May 14, 2020
Apr 28, 2020 08:00AM Daré Bioscience CEO to Participate in Maxim Group’s Infectious Disease Virtual Conference
Apr 23, 2020 08:05AM Dare Bioscience (DARE) Enters Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
Apr 23, 2020 08:00AM Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
Apr 1, 2020 08:00AM Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene®
View More Recent Stories View Older Stories